Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie

Translated title of the contribution: Fixed dosing of monoclonal antibodies in oncology

Jeroen J.M.A. Hendrikx, John B.A.G. Haanen, Emile Voest, Jan H.M. Schellens, Alwin D.R. Huitema, En Jos H. Beijnen

Research output: Contribution to journalArticlepeer-review


Fixed dosing of monoclonal antibodies in oncology BACKGROUND and OBJECTIVE Most monoclonal antibodies in oncology are administered using body size-based dosing schedules. This is believed to correctforvariability in both drug distribution and elimination between patients. However, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body size-based dosing.DESIGN and METHODS We summarized effects of body weight on the pharmacokinetic parameters of monoclonal antibodies in oncology and show that a fixed dose for most of these drugs is justified. RESULTS and CONCLUSION We show that fixed dosing is justified and can improve efficiency of compounding. Moreover, drug spillage can be reduced and medication errors may become less likely.

Translated title of the contributionFixed dosing of monoclonal antibodies in oncology
Original languageDutch
Pages (from-to)21-30
Number of pages10
JournalPharmaceutisch Weekblad
Issue number35
Publication statusPublished - 31 Aug 2018
Externally publishedYes


Dive into the research topics of 'Fixed dosing of monoclonal antibodies in oncology'. Together they form a unique fingerprint.

Cite this